Up 40%! Is it too late for me to grab some shares of this skyrocketing FTSE 100 giant?

With the share price soaring, our writer’s kicking himself for not buying this FTSE 100 share when he reported on it a month ago. Is he too late?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Artillery rocket system aimed to the sky and soldiers at sunset.

Image source: Getty Images

Just over a month ago, I wrote about how the FTSE 100 defence giant Melrose Industries (LSE: MRO) is gearing up for growth. At the time, it had just begun a mild recovery after hitting a yearly low of 417p.

Fast-forward 32 days and it’s now up 40% since! Buying the shares then would have netted me some decent returns. But as a risk-averse investor with a long-term view, I made a decision that best fits my strategy.

So have things changed?

In my previous article, I spoke of the Risk and Revenue Sharing Partnerships (RRSPs) that ignited a price recovery.

The market’s reaction to the RRSPs seems even better than expected but Trump’s election win no doubt helped push the price up even further. Melrose is a key supplier of aerospace components to civil and defence companies globally, with the US being a big customer.

The US stock market has been on a record run since the election announcement. However, Trump’s recent trade tariff plans have thrown a spanner in the works, rocking global markets.

Revaluating metrics

Naturally, the rapid price growth has pushed up its price-to-sales (P/S) ratio. Now at 2.2, I suspect this number will continue to rise until the next earnings call.

Earnings per share (EPS) for the second half of 2024 are expected to rise to 14p (currently 11p). This is down slightly from previous forecasts, with the earnings growth rate now reduced to 99.5% from 106% last month.

One risk I’ve identified is debt. At £1.17bn, it’s quite high in comparison to fairly low cash reserves of £190m. This puts some strain on its balance sheet, as it may struggle to cover interest payments.

Overall, growth potential remains strong and Melrose is likely to regain profitability next year. But that doesn’t mean it’ll be plain sailing. 

US trade tariffs

Despite the positive developments and price action, analysts don’t expect much growth in the coming year. The average 12-month price target’s only 10% up from today’s price. 

I believe the key reason for this is fear of potential US trade tariffs dampening profits in 2025.

So far, President-elect Trump’s outlined his plans for tariffs on Canada, Mexico and China and many analysts fear Europe could be next. Some feel the UK is at a disadvantage since leaving the EU. The Guardian‘s William Keegan recently said: “If we were part of a European Union trade negotiating team, we should be in a far stronger position.”

By contrast, Business and Trade Secretary Jonathan Reynolds told lawmakers last week that “Britain would not shy away from making the case for free trade to the Trump administration“.

As I mentioned in my previous article, RRSPs promise solid cash flows for Melrose until at least 2050. But without a beneficial deal in place, unfavourable trading expenses could eat into those revenues.

Even if tariffs are imposed on the UK, there could be concessions for certain industries like defence. Until Trump takes power in January, we simply won’t know.

While I may have missed out on some gains, I won’t be buying the shares until there’s more clarity regarding tariffs.

Mark Hartley has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Market Movers

Down 7%! Why on earth are Imperial Brands shares plummeting today?

Imperial Brands shares are in freefall after a negative reception to fresh trading news. Is the party finally over for…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »